All News
EULAR Abstract Archive
OP0283 (2024)
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Zoe @ZoeClarkOsteo from @NASSexercise @NASSchiefexec presenting her work from the Your SpAce self-management programme which covers topics on pain, fatigue, flares and much more #EULAR2024 @RheumNow https://t.co/q81JDHu7Oj
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
CAR-T - autologous vs allogenic , need for full induction , safety of retreatment, CAR-T lymphoma/leukaemia, cost, ideal candidate ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
opposing point of view to previous post @RheumNow #EULAR2024 https://t.co/T72r8kXF1j
Peter Nash drpnash ( View Tweet)
#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Frank Buttgereit discusses potential reason for ceiling effect in RA and questions why we don’t use more combination therapy in RA (including low dose of of GC), using the example of Hypertension guidelines
Is long term low dose GC in RA really a desirable option?
@RheumNow… https://t.co/Nc7lldN7Nd https://t.co/63K96uuhKG
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Tips to help in self-management. Procrastination is a huge barrier to self-management. Delegate and prioritise #EULAR2024 Andrea Marques @RheumNow https://t.co/SbQgOMwqL0
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Steroids are often started before pts see a rheumatologist
This associates with long-term low-dose steroid use
Need better collaboration between referrers and rheum to reduce this avoidable steroid burden
POS0137 @RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Data form TARA trial Taper in RA remission
Flare free survival at 2 yrs 35%
Risk of flare is similar in ACPA+ & ACPA- RA
Risk of flare is similar if taper TNFi first or csDMARD first
@RheumNow #EULAR2024 POS0405 https://t.co/89gAglHUcw
Aurelie Najm AurelieRheumo ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
´The health care professionals ànd caregivers also need to be well in order to deliver care for patients’ Andrea Marques speaking at the self-management session at #EULAR2024 @RheumNow https://t.co/BrEHPTbbti
Dr. Antoni Chan synovialjoints ( View Tweet)
Autoantibody measures in 5 scandinavian cohorts 6900+ RA pts
Four cit-peptides w/ high frequency
Cit Fibb36-52 (51%) Cit Fibb60-74-Cit3 (59%) Cit Fil307-324 (54%) Cit Vim60-75-Cit1 (63%)
Capture 97% of IgG CCP2+ & 22% IgG CCP2-
42% of all pts + IgG anti-Carb or Acet peptides… https://t.co/yYr6AzgipM https://t.co/6dP6Sgi3yB
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2024
@AilsaBosworth1 highlights the programmes available for pts diagnosed with #RA via the @NRAS_UK platform
SMILE-RA and RightStart are great resources for self-management, can highly recommend to all clinicians!
@RheumNow https://t.co/SgAMKkcycE
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
Just some of the barriers to supporting patients in self-management.
Important to note the array of factors at play, some easier to address than others but all should be acknowledged to tailor individual self-management guidance.
@RheumNow @ElenaNikiUK #EULAR2024 https://t.co/GJM35l275V
Mrinalini Dey DrMiniDey ( View Tweet)
« Glucocorticoids are such old drugs and we still use them so much » says Josef Smolen
Summary slide from « 75th anniversary of GCd, what have we learnt? »
@RheumNow #EULAR2024 https://t.co/XSRt44zupw
Aurelie Najm AurelieRheumo ( View Tweet)